Related Experiment Video
Updated: Aug 17, 2025
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
Published on: September 28, 2022
Epstein-Barr Virus Glycoprotein Antibody Titers and Risk of Nasopharyngeal Carcinoma
Anna E Coghill1, Andrew McGuire2,3,4, Sweta Sinha1
1Cancer Epidemiology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Abstract:
We evaluated antibody against Epstein-Barr virus glycoproteins (gp350, gH/gL, gB, gp42) in 97 nasopharyngeal carcinoma (NPC) cases and 97 cancer-free controls. Each unit increase in log-transformed antibody against gp350 and gH/gL was associated with 2.27 (95% confidence interval [CI], 1.20-4.29) and 2.18 (95% CI, 1.22-3.90) higher odds of NPC, respectively. This association was more apparent for NPC diagnosed within 5 years of antibody measurement.
More Related Videos
09:43An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
08:44Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022